State Street Corp Cuts Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

State Street Corp lessened its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,782,883 shares of the biotechnology company's stock after selling 90,352 shares during the quarter. State Street Corp owned about 5.62% of REGENXBIO worth $29,192,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Integral Health Asset Management LLC increased its stake in shares of REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock worth $11,115,000 after acquiring an additional 190,000 shares during the period. Quest Partners LLC increased its position in REGENXBIO by 11,731.0% during the 2nd quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company's stock worth $491,000 after purchasing an additional 41,645 shares during the period. BNP Paribas Financial Markets raised its stake in shares of REGENXBIO by 602.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after buying an additional 17,533 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of REGENXBIO by 630.9% in the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company's stock valued at $1,711,000 after buying an additional 126,249 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in shares of REGENXBIO in the second quarter valued at approximately $494,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RGNX has been the subject of several research analyst reports. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Royal Bank of Canada reiterated an "outperform" rating and issued a $35.00 price target on shares of REGENXBIO in a report on Wednesday, December 11th. HC Wainwright decreased their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday, November 21st. Morgan Stanley reaffirmed an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Finally, StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, September 20th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $35.27.

Insider Activity at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the company's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the transaction, the director now directly owns 11,286 shares in the company, valued at approximately $114,101.46. This represents a 46.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 13.13% of the company's stock.

REGENXBIO Stock Performance

REGENXBIO stock traded up $0.21 during midday trading on Friday, reaching $7.62. 10,645,573 shares of the company were exchanged, compared to its average volume of 712,177. The company has a market capitalization of $377.53 million, a price-to-earnings ratio of -1.51 and a beta of 1.24. REGENXBIO Inc. has a 1 year low of $7.21 and a 1 year high of $28.80. The firm's 50-day simple moving average is $9.58 and its 200-day simple moving average is $11.15.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.